Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 210-214

  Schraffordt Koops, Heimen ^a   Eggermont, Alexander M M ^b   Liénard, Danielle ^c   Kroon, Bin B R ^d   Hoekstra, Harald J ^a   Van Geel, Albertus N ^b   Nieweg, Omgo E ^d   Lejeune, Ferdinand J ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Antineoplastic agents; Combined modality therapy; Drug dose response relationship; Extremities; Induced hyperthermia; Interferon gamma; Melphalan; Regional perfusion; Remission induction; Sarcoma; Tumor necrosis factor

Indexed keywords

CHLORMETHINE; DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; HYPERTHERMIC THERAPY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMB PERFUSION; LIMB SALVAGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON-GAMMA, RECOMBINANT; MELPHALAN; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 6844255234     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<210::AID-SSU4>3.0.CO;2-B     Document Type: Review

References (31)

1. Hoekstra HJ, Schraffordt Koops HS, Oldhoff J: Soft tissue sarcoma of the extremity [Review]. Eur J Surg Oncol 1994;20:3-6.
2. Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al: MRI and CT in the preoperative evaluation of soft-tissue tumors. Arch Orthop Trauma Surg 1991;110:162-164.
3. Eilber FR, Giuliano AE, Huth JF, Morton DL: A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft tissue sarcoma. Am J Clin Oncol 1988;11:39-45.
4. Hoekstra HJ, Mehta DM, Wijffels RT, et al: Local tumor control by intra-operative radiotherapy (IORT): a pilot experience. Eur J Surg Oncol 1991;17:364-369.
5. Bramwell V, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the EORTC. J Clin Oncol 1994;12:1137-1149.
6. Creech OJ, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-632.
7. Lienard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
8. Olieman AF, van Ginkel RJ, Hoekstra HJ, et al: Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64-69.
9. Eggermont AM, Liènard D, Schraffordt Koops H, et al: Treatment of irresectable soft tissue sarcomas of the limbs by isolated perfusion with high-dose TNF-α in combination with interferon-γ and melphalan. In Fiers W, Buurman W (eds): "Tumour necrosis factor: molecular and cellular biology and clinical relevance." Basel: Karger; 1993. p. 239-243.
10. Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H: Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987;11:527-533.
11. Hoekstra HJ, Naujocks T, Beekhuis H, et al: Continuous leakage monitoring during hyperthermic regional isolated perfusion of the lower limb, techniques and results. Reg Cancer Treat 1992;4:301-304.
12. Krementz ET, Carter RD, Sutherland CM, Hutton I: Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977;185:555-564.
13. Pommier RF, Moseley HS, Cohen J, et al: Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988;155:667-671.
14. Klaase JM, Kroon BB, Benckhuijsen C, et al: Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-621.
15. Rossi CR, Vecchiato A, Foletto M, et al: Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-2146.
16. Lehti PM, Moseley HS, Janoff K, et al: Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986;162:149-152.
17. McBride CM: Sarcoma of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974;109:304-308.
18. Di Filippo F, Calabrò AM, Cavallari A, et al: The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 1988;12:332-339.
19. Stehlin JS Jr, de Ipolyi PD, Giovanella BC, et al: Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 1975;130:643-646.
20. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J: Results of isolated regional perfusion in the treatment of malignant soft tissue tumours of the extremities. Cancer 1987;60:1703-1707.
21. Braat RP, Wieberdink J, Slooten EA van, et al: Regional perfusion with adriamycin in soft tissue sarcomas. In Schwemmle K, Aigner K (eds): "Vascular perfusion in cancer therapy." Berlin: Springer Verlag; 1983. p. 86:260-263.
22. Krementz ET, Muchmore JH: Soft tissue sarcomas: behavior and management. "Yearbook of surgery". Chicago: Yearbook Medical; 1983. p. 147-196.
23. Aigner K, Hild P, Breithaupt H, et al: Isolated extremity perfusion with DTIC. An experimental and clinical study. Anticancer Res 3:87-93;1983.
24. Fraker DL, Alexander HR, Pass HJ: Biologic therapy with TNF: systemic administration and isolation-perfusion. In DeVita V Jr, Hellman S, Rosenberg SA (eds): "Biolosic therapy of cancer". 2nd ed. Philadelphia: Lippincott, 1995, 329-345.
25. Schraffordt Koops H, Liènard D, Eggermont AM, et al: Isolated limb perfusion with high dose TNF-alpha, gamma-IFN, and melphalan in patients with irresectable soft tissue sarcomas. A highly effective limb saving procedure [Abstract]. In 46th Annual Cancer Symposium. The Society of Surgical Oncology; 18-21 March 1993; Los Angeles. Los Angeles: Society of Surgical Oncology 1993;4:1.
26. Hill S, Fawcett WJ, Sheldon J, et al: Low-dose tumour necrosis factor alpha and melphalan in hypothermic isolated perfusion. Br J Surg 80:995-997;1993.
27. Fraker DL, Alexander HR, Andrich M, Rosenberg SA: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose escalation study. J Clin Oncol 1996;14:479-489.
28. Eggermont AM, Schraffordt Koops H, Liènard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [comment in: J Clin Oncol 1996;14:2627-2630; J Clin Oncol 1997;15:2174-2175]. J Clin Oncol 1996;14:2653-2665.
29. Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative Multicentre European Experience. Ann Surg 1996;224:756-765.
30. van Ginkel RJ, Hoekstra HJ, Eggermont AM, et al: Isolated limb perfusion of an irradiated foot with tumour necrosis factor, interferon and melphalan. Arch Surg 1996;131:672-674.
31. Brennan MF, Shiu MH: Soft tissue sarcoma of the extremities. In Shiu MH, Brennan MF (eds): "Surgical management of soft tissue sarcomas". Philadelphia: Lea and Feibeger; 1989. p. 79-124.